Thermo Fisher Ponders Filling Edman Sequencer Gap; Is there Enough Demand?

On the heels of Applied Biosystems’ pullout from the Edman sequencing market, leaving the United States without a player in the space, Thermo Fisher is at least exploring the possibility of entering the arena by developing either its own Edman sequencer or an alternative technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories